Replimune Group FY2027 EPS Decreased by Leerink Partnrs

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Stock analysts at Leerink Partnrs decreased their FY2027 earnings per share (EPS) estimates for shares of Replimune Group in a note issued to investors on Monday, October 20th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($1.51) for the year, down from their prior estimate of ($1.20). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Replimune Group's current full-year earnings is ($2.97) per share.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12).

Other equities research analysts have also recently issued reports about the stock. HC Wainwright restated a "neutral" rating on shares of Replimune Group in a report on Monday, September 8th. Piper Sandler raised Replimune Group from a "neutral" rating to an "overweight" rating and set a $13.00 price target on the stock in a research note on Monday. Leerink Partners raised Replimune Group from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $3.00 to $13.00 in a research note on Monday. BMO Capital Markets cut Replimune Group from an "outperform" rating to an "underperform" rating and cut their target price for the stock from $27.00 to $2.00 in a report on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. upgraded shares of Replimune Group from an "underweight" rating to a "neutral" rating and set a $11.00 price objective on the stock in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $11.00.

Replimune Group Stock Performance

Shares of REPL stock opened at $8.30 on Thursday. The firm has a 50 day moving average of $5.23 and a 200-day moving average of $7.29. The company has a market cap of $647.90 million, a price-to-earnings ratio of -2.56 and a beta of 0.42. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. Replimune Group has a 52 week low of $2.68 and a 52 week high of $17.00.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in REPL. Vanguard Group Inc. grew its holdings in shares of Replimune Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock valued at $37,372,000 after acquiring an additional 237,185 shares in the last quarter. Millennium Management LLC grew its stake in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock valued at $11,927,000 after purchasing an additional 33,574 shares during the period. MPM Bioimpact LLC raised its stake in shares of Replimune Group by 3.9% during the 1st quarter. MPM Bioimpact LLC now owns 987,036 shares of the company's stock worth $9,624,000 after purchasing an additional 37,036 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of Replimune Group by 9.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company's stock worth $9,266,000 after buying an additional 80,640 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock valued at $6,729,000 after buying an additional 119,145 shares during the period. Hedge funds and other institutional investors own 92.53% of the company's stock.

Insiders Place Their Bets

In other news, CFO Emily Luisa Hill sold 9,154 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the sale, the chief financial officer owned 134,368 shares in the company, valued at $721,556.16. This represents a 6.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 5.20% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.